Direct Matrix Metalloproteinase Enhancement of Transscleral Permeability

Lindsey, James D.; Crowston, Jonathan G; Tran, Ailinh J; Morris, Christine; Weinreb, Robert N.

doi:10.1167/iovs.06-0334

Cited by 18 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, PG analogues seem to induce extracellular matrix remodelling due to the PG F‐receptor‐mediated increased synthesis of some matrix metalloproteinases (Lindsey et al. ; Honda et al. ) in several locations of the anterior segment (Weinreb et al.…”

Section: Discussionmentioning

confidence: 99%

“…; Wierzbowska & Stankiewicz ; Lindsey et al. ). In addition, PG analogues slightly decrease the CCT in human eyes (Viestenz et al.…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, PG analogues seem to induce extracellular matrix remodelling due to the PG F-receptormediated increased synthesis of some matrix metalloproteinases (Lindsey et al 2007;Honda et al 2010) in several locations of the anterior segment (Weinreb et al 1997;Gaton et al 2001;Wierzbowska & Stankiewicz 2006;Lindsey et al 2007). In addition, PG analogues slightly decrease the CCT in human eyes (Viestenz et al 2004) and may increase the keratocyte density in the corneal stroma, both of which may be due to drug-induced changes in the extracellular matrix (Bergonzi et al 2012).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of topical prostaglandin analogues on corneal hysteresis

Bolívar

Sánchez-Barahona

Teus

et al. 2015

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Purpose: To evaluate possible changes in corneal hysteresis (CH) after topical treatment with a prostaglandin analogue in medication-na€ ıve eyes. Methods: This was a prospective, observational cohort study. Sixty-eight eyes of 68 patients were prospectively included who were newly diagnosed with primary open-angle glaucoma or ocular hypertension in our institution. All patients were treatment-na€ ıve. Patients were evaluated at baseline and after 6 months of treatment with latanoprost in the eye with the lower intraocular pressure (IOP) measured by Goldmann applanation tonometry (GAT). The ocular response analyzer was used to measure CH. Results: CH increased significantly (p = 0.0001) from 8.96 AE 2.3 mmHg to 9.79 AE 1.97 mmHg, and this increase was correlated significantly (p = 0.0001, r = 0.64, r 2 = 0.41) with the basal CH. We identified a weak but significant (r 2 = 0.06, p = 0.01) relationship between the basal CH and the drug-induced reduction of the GAT IOP. Nevertheless, the increase in the drug-induced CH was not correlated with the decrease in the GAT IOP. Conclusion: Treatment with latanoprost increases CH. The CH increase was not correlated with the drug-induced decrease in the GAT IOP, which suggested a direct effect of latanoprost on the viscoelastic corneal properties.

show abstract

Section: Discussionmentioning

confidence: 99%

“…; Wierzbowska & Stankiewicz ; Lindsey et al. ). In addition, PG analogues slightly decrease the CCT in human eyes (Viestenz et al.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of topical prostaglandin analogues on corneal hysteresis

Bolívar

Sánchez-Barahona

Teus

et al. 2015

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Ex vivo permeability studies confirmed that TA is able to diffuse through rabbit sclera in a sustained profile, following a zero-order kinetic model. Strong tissue binding was observed, providing a drug depot [101].…”

Section: Nanostructured Lipid Carriersmentioning

confidence: 99%

Nanoparticulate Transscleral Ocular Drug Delivery

Shah¹,

Shah²,

Groshev³

et al. 2014

J Biomol Res Ther

View full text Add to dashboard Cite

Ocular drug delivery is one of the most challenging areas of drug delivery due to the unique mostly avascular nature of the major eye structures and presence of two blood barriers. Effectiveness of a more conventional systemic delivery falls short due to low drug levels in the eye tissue. Periocular approaches require penetration of fibrous sclera and present their own limitations. Utilization of nanotechnology presents new avenue of drug system development with potential to penetrate protective barriers and sustain ample tissue saturation. More specifically, transscleral delivery permits a range of applications in targeted delivery, gene, stem cell, protein and peptides, oligonucleotide, and ribozyme therapies. The exciting range of current applications is expounded in this review.

show abstract

“…However, the invasive routes of administration can be associated with complications such as intraocular bleeding, pain, and discomfort to the patient which result in poor patient compliance (Sampat & Garg, 2010). Hence, noninvasive interventions such as penetration enhancers (Mahaling & Katti, 2016a; K. Okabe et al, 2005), cell-penetrating peptides (Johnson, Cashman, & Kumar-Singh, 2008), matrix metalloproteinases (MMPs, to degrade scleral tissue) (Lindsey, Crowston, Tran, Morris, & Weinreb, 2007), and prostaglandins (to enhance MMPs activity) (Aihara, Lindsey, & Weinreb, 2001) have been explored for improving bioavailability of administered drugs. All these approaches are associated with toxicity that can cause damage to sensitive eye structures (Burgalassi, Chetoni, Monti, & Saettone, 2001).…”

Section: Introductionmentioning

confidence: 99%

Fundamentals, challenges, and nanomedicine‐based solutions for ocular diseases

Srinivasarao

Lohiya

Katti

2018

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

The eye consists of sensitive, compactly adjoined tissue structures which act as strong physical (static) and physiological (dynamic) barriers that prevent entry of foreign bodies into the eye. Together, these barriers reduce the bioavailability of topically and intraocularly administered medicaments thus demanding frequent drug administration for the treatment of chronic eye diseases. Hence, development of drug delivery systems (DDS) that can be retained in ocular tissues for longer durations can help to reduce the frequency of drug administration, whereas, delivery systems that traverse through ocular barriers may offer higher bioavailability of administered drugs to otherwise inaccessible ocular tissues. These objectives can be partially/fully achieved using nanoparticulate/colloidal DDS. Colloidal DDS, due to their nanodimensions, undergo internalization by cells which enables transport of drugs through ocular barriers. Furthermore, nanoparticles can prolong duration of drug release and can increase residence time of entrapped cargo molecules in ocular tissues. Together, these aspects facilitate a higher bioavailability, prolonged therapeutic effect and reduced frequency of drug administration for the effective treatment of chronic ocular diseases. Hence, nanocarriers have been widely explored for ophthalmic drug delivery applications. In this review, we discuss the anatomy of ocular tissues along with their barrier properties. We then discuss ocular diseases along with the various routes of drug administration and pathways of drug transport in the eye. The next section discusses the influence of physicochemical properties of therapeutic molecules on their ocular distribution and conventional and advanced (nanoparticulate/colloidal DDS) drug formulations that are used for the treatment of ocular diseases.

show abstract

Direct Matrix Metalloproteinase Enhancement of Transscleral Permeability

Abstract: These results show that MMP-1, -2, and -14 can directly increase transscleral permeability and support the view that the increased MMP-1 and -2 observed after topical PG treatment could contribute to increased uveoscleral outflow.

Cited by 18 publications

References 14 publications

Effect of topical prostaglandin analogues on corneal hysteresis

Effect of topical prostaglandin analogues on corneal hysteresis

Nanoparticulate Transscleral Ocular Drug Delivery

Fundamentals, challenges, and nanomedicine‐based solutions for ocular diseases

Contact Info

Product

Resources

About